Analysts think CYCC stock price could increase by 564%
Jul 30, 2024, 6:26 AM
-30.77%
What does CYCC do
Cyclacel Pharmaceuticals Inc, based in Berkeley Heights, New Jersey, is a clinical-stage biopharmaceutical company focused on developing cancer treatments through programs in cell cycle, transcriptional regulation, and mitosis control. Key projects include fadraciclib, a CDK9 inhibitor for various cancers, and plogosertib, a potent PLK1 inhibitor targeting solid tumors and hematological malignancies.
4 analysts think CYCC stock price will increase by 563.91%. The current median analyst target is $11.22 compared to a current stock price of $1.69. The lowest analysts target is $11.11 and the highest analyst target is $11.55.
📡️ Health Care
Price Target
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.